126 results about "Immunologic Technique" patented technology

The present invention belongs to the technical field of immunology, and in particular, relates to a humanized nanoantibody against TNF-α and its application. The present invention provides a humanized nanoantibody against TNF-α, and a recombinant humanized nanoantibody against TNF-α prepared by expressing the gene of the humanized nanoantibody against TNF-α. The humanized nanoantibody against TNF-α prepared by the present invention can specifically recognize the TNF-α antigen, thereby accurately targeting the inflammatory site, reducing nonspecific reactions, and improving the therapeutic effect.

The invention belongs to the technical field of immunology, and particularly relates to an anti-TNF-alpha nano antibody and application thereof. The invention provides an anti-TNF (Tumor Necrosis Factor)-alpha nano antibody. The anti-TNF-alpha recombinant nano antibody is prepared by performing gene expression on the anti-TNF-alpha nano antibody. The anti-TNF-alpha nano antibody prepared by the invention can specifically recognize a TNF-alpha antigen so as to accurately target an inflammation part, reduce non-specific reaction and improve the treatment effect.

The invention relates to the technical field of immunology, and discloses a QS-21 composite adjuvant as well as a preparation method and application thereof, and the QS-21 composite adjuvant comprises the following components in parts by weight: 0.1-0.5 part of QS-21; 4 to 6 parts of liposome; 0.05 to 0.1 part of CpG oligonucleotide; 0.1 to 0.3 part of a freeze-drying protective agent; 0.2 to 0.5 part of a stabilizing agent; 3 to 5 parts of propylene glycol; 1-2 parts of ethanol; 5-15 parts of an organic solvent chloroform; the liposome is prepared from the following components in parts by weight: 3 to 4 parts of phospholipid distearate; and 1-2 parts of amino lipid. By compounding the liposome carrier and the QS-21, adding the CpG oligonucleotide and optimizing the freeze-drying protective agent, the loading efficiency of the immunologic adjuvant, the immune effect stability and the restorability after freeze-drying are improved, and the durability and efficacy of immune response are enhanced.

The invention belongs to the technical field of immunology, and particularly relates to an anti-IL-6 nano antibody, a recombinant nano antibody, a recombinant vector and application. The anti-IL-6 nano antibody disclosed by the invention comprises a heavy chain variable region containing CDR1, CDR2 and CDR3, and has the functions of identifying and combining IL-6. The invention also discloses a recombinant nano antibody containing the nano antibody, a recombinant vector and a detection agent, and applications of the nano antibody, the recombinant nano antibody, the recombinant vector and the detection agent in preparation of drugs for treating IL-6 related diseases. The nano antibody, the recombinant nano antibody and the recombinant vector provided by the invention can recognize and combine IL-6, and have a potential effect of treating IL-6-related diseases.

The invention belongs to the technical field of immunology, and particularly relates to a targeted IL-6 biological nano antibody and application thereof. The invention discloses a nano antibody for targeting IL-6, which comprises a heavy chain variable region containing CDR1, CDR2 and CDR3, and has the functions of identifying and combining IL-6. The invention also discloses a composition containing the nano antibody or the IL-6 binding molecule, and an application of the composition containing the nano antibody and the IL-6 binding molecule in preparation of drugs for treating IL-6 related diseases. The nano antibody, the BCMA binding molecule and the composition can recognize and bind IL-6, and have a potential effect of treating IL-6 related diseases.

The invention belongs to the technical field of immunology, and particularly relates to an anti-IL-6 humanized nano antibody, a recombinant humanized nano antibody and application. The inventor-derived nano antibody 2H3 comprises complementary determining regions CDR1-CDR3, the amino acid sequence of the CDR1 is as shown in SEQ ID NO.13, the amino acid sequence of the CDR2 is as shown in SEQ ID NO.14, and the amino acid sequence of the CDR3 is as shown in SEQ ID NO.15. The inventor-derived nano antibody 2H3 has the advantages that the complementary determining regions CDR1-CDR3 can be used for preparing the antibody; the humanized nano antibody can block the combination of IL-6 and a receptor thereof while keeping the affinity with IL-6, and has a wide application prospect in the preparation of medicines for preventing and / or treating tumors. The humanized nano antibody is low in molecular weight, reduces the immune risk caused by heterology, is more beneficial to penetrating a blood brain barrier, and is easier to reach the interior of a tumor to play a therapeutic effect.

The invention discloses an African swine fever virus p30 protein antibody and application thereof. When the African swine fever virus p30 protein antibody is used for a competitive ELISA method, a serum sample with the p30 antibody after African swine fever virus infection can be rapidly and accurately detected, the detection time is shortened, the detection steps are simplified, the African swine fever virus p30 protein antibody has the characteristics of rapidness and high-throughput detection, and a reliable immunological technology is provided for rapidly and efficiently detecting African swine fever virus infection.

The invention belongs to the technical field of molecular biology and immunology, and provides an alpaca-derived nano antibody specifically bound with a simian vacuolar virus 40 large T antigen SV40LTA and application of the alpaca-derived nano antibody. The invention relates to a heavy chain antibody, which has a heavy chain variable region VHH, the VHH comprises the following CDR: CDR1 with an amino acid sequence as shown in SEQ ID NO: 1, CDR2 with an amino acid sequence as shown in SEQ ID NO: 2, and CDR3 with an amino acid sequence as shown in SEQ ID NO: 3, the VHH comprises four frame regions of FR1-4, and FR1, FR2, FR3 and FR4 and CDR1, CDR2 and CDR3 are arranged in a staggered manner in sequence. The antibody is high in neutralizing activity and strong in binding capacity with SV40LTA, and the equilibrium dissociation constant is less than 0.1 nM; the monoclonal antibody has the advantages that the monoclonal antibody can effectively recognize SV40LTA, the molecular weight is small, the immunogenicity is small, the solubility and stability are better, and the CDR region is longer; and a potential application value is provided for SV40LTA detection.

The invention discloses an indirect ELISA kit for rapidly detecting a porcine epidemic diarrhea virus IgA antibody and application of the indirect ELISA kit, and belongs to the technical field of immunology. The invention provides a recombinant PEDV-RBD protein. The amino acid sequence of the recombinant PEDV-RBD protein is shown as SEQ ID NO. 3. The indirect ELISA kit for detecting the porcine epidemic diarrhea virus IgA antibody is constructed based on the recombinant PEDV-RBD protein, the PEDV IgA antibody in pig breast milk or serum can be accurately captured for detection, the kit has the advantages of high sensitivity and strong specificity, and a technical means is provided for prevention and control of porcine epidemic diarrhea.

The invention belongs to the technical field of immunology, and particularly relates to an anti-TNF-alpha nano antibody as well as a preparation method and application thereof. The invention provides an anti-TNF (Tumor Necrosis Factor)-alpha nano antibody. The anti-TNF-alpha recombinant nano antibody is prepared by expressing a gene of the anti-TNF-alpha nano antibody. The anti-TNF-alpha nano antibody prepared by the invention can specifically recognize a TNF-alpha antigen so as to accurately target an inflammation part, reduce non-specific reaction and improve the treatment effect.

The invention belongs to the technical field of immunology, and particularly relates to an anti-mandarin fish immune globulin D (IgD) monoclonal antibody as well as a preparation method and application thereof. The invention provides a hybridoma cell strain 5C7 capable of secreting an anti-fish IgD monoclonal antibody or an antigen binding fragment thereof for the first time, the hybridoma cell strain 5C7 is preserved in China Center for Type Culture Collection on January 16, 2025, and the preservation number is CCTCC NO: C202550. The anti-mandarin fish IgD monoclonal antibody or the antigen binding fragment thereof can be subjected to specific reaction with mandarin fish secreting type IgD protein and B cell surface film type IgD, can be applied to detection of IgD in a mandarin fish serum sample, and can also be applied to detection of IgD + B cell surface markers.

The invention relates to the technical field of livestock immunology, in particular to a mouse anti-bovine IgG monoclonal antibody and application thereof. The mouse anti-bovine IgG monoclonal antibody provided by the invention can be specifically combined with bovine IgG, has no cross reaction with other similar proteins, has relatively high affinity with bovine IgG, and has relatively high stability; based on the antibody, a double-antibody sandwich ELISA method for detecting bovine IgG has high sensitivity, specificity and accuracy, accurate and high-throughput detection of the IgG content in bovine serum or other serum analogues or products containing bovine IgG can be realized, and the antibody has a good application prospect in bovine IgG detection.

The invention provides a reagent for detecting avian leukosis virus, a nano-enzyme immunochromatography test strip and application of the nano-enzyme immunochromatography test strip, and belongs to the technical field of immunology. Aiming at the problems that the existing avian leukosis virus detection method is complicated in operation, time-consuming or strong in equipment dependence, the reagent comprises a capture antibody and a detection antibody; a heavy chain variable region of the monoclonal antibody A comprises an amino acid sequence as shown in SEQ ID NO: 1, and a light chain variable region of the monoclonal antibody A comprises an amino acid sequence as shown in SEQ ID NO: 2; a heavy chain variable region of the monoclonal antibody B comprises an amino acid sequence as shown in SEQ ID NO: 5, and a light chain variable region of the monoclonal antibody B comprises an amino acid sequence as shown in SEQ ID NO: 6; the antigen binding fragment is a Fab fragment, an F (ab) 2 fragment or a single-chain Fv fragment. The reagent is mainly used for detecting avian leukosis virus, and is suitable for detecting samples such as cloaca swab, meconium, egg white or serum of poultry.

The application belongs to the technical field of biological medicine and immunology, and particularly relates to a single-domain antibody targeting cross binding of human and cynomolgus monkey CD46 and application thereof. The application utilizes alpaca to generate nanoscale antibodies, the molecular weight of which is about 15 kDa, and the nanoscale antibodies can more efficiently penetrate solid tumor tissues or cross blood-brain barrier, and the binding efficiency of the antibodies and target points is as high as possible. The 11 single-domain antibodies prepared by the application have specificity of anti-human and anti-cynomolgus monkey CD46, and in the binding detection with CD46 target proteins and CD46 overexpression cells, the binding efficiency is significantly better than that of Anti-CD46 humanization antibody, and the single-domain antibodies can be used for tumor treatment. Meanwhile, the single-domain antibodies have cross binding ability of cross species, and can be directly used for preclinical pharmacodynamics and safety evaluation, without the need of developing species-specific alternative antibodies, so that the application achieves 'one target and double effect'.

The invention belongs to the technical field of immunology, and particularly discloses an in-vitro preparation method and application of an induced follicular regulatory T cell iTfr.The in-vitro preparation method comprises the steps that mouse spleen single-cell suspension or healthy human peripheral blood is obtained, peripheral blood mononuclear cells are obtained, then initial CD4 + T cells are obtained through immunomagnetic bead sorting, and iTfr cells are obtained; then carrying out induced differentiation by using an antibody and a specific cytokine, and carrying out continuous stimulation and culture by adopting two different cytokine polarization conditions, so as to obtain the iTfr cell. The invention provides a method for preparing the iTfr cells in vitro, which is expected to obtain an enough number of induced follicular regulatory T cells, and provides an important tool and a treatment means for in vitro research of immune tolerance related diseases such as autoimmune diseases and organ transplantation.

The invention belongs to the technical field of in-vitro diagnostic reagents, and particularly relates to application of a detection reagent for GDF15 protein in extracellular vesicles in preparation of a prostate cancer diagnosis and / or staging kit. According to the invention, enrichment and proteomics detection are carried out on plasma EVs of patients with prostatic cancer (PCa) and benign prostatic hyperplasia (BPH), and through bioinformatics analysis, a potential EV protein marker GDF15 which can be used for early diagnosis of PCa is screened for the first time. The GDF15 protein is verified in a plurality of groups of new clinical queues by further adopting an immunological technology and a targeted quantitative mass spectrometry technology, and the distinguishing ability of the GDF15 protein to PCa and BPH and the distinguishing ability of the GDF15 protein to different PCa stages are determined. The method is expected to promote noninvasive precise diagnosis of clinical PCa, and has a good application prospect.

The invention belongs to the technical field of immunology, and particularly relates to an anti-TNF-alpha nano antibody as well as a preparation method and application thereof. The anti-TNF-alpha nano antibody sequence with high affinity is obtained through four rounds of optimized phage screening, and further, the soluble expression quantity of the nano antibody is improved by utilizing a pET26a (+)-BL21 expression system and combining a codon optimization technology. The nano antibody can be used for preparing a reagent for treating or diagnosing TNF-alpha related diseases, and has extremely high practical application value.

The invention belongs to the technical field of immunology, and provides a recombinant C-type single-domain nano antibody combined with CDH17 and application of the recombinant C-type single-domain nano antibody. According to the invention, an antibody with binding capacity to CDH17 is screened by using a phage display technology, then m01s is used as a skeleton recombinant antibody, and the C-type single-domain antibody with high affinity activity is obtained through antibody recombination. The obtained recombinant C-type single-domain nano antibody combined with CDH17 can be used as an indicator for diagnosis and prognosis of cancers, and is expected to become a candidate drug of CAR-T drugs for gastric cancer, breast cancer, colon cancer and the like due to high affinity to tumor cells.

The application provides an anti-IL-17A nanobody, a pharmaceutical composition, a method and a use, and belongs to the technical field of cellular immunology. The antibody provided by the application comprises a complementarity determining region HCDR, and the complementarity determining region HCDR comprises: (1) HCDR1 with an amino acid sequence as shown in SEQ ID NO:1, HCDR2 with an amino acid sequence as shown in SEQ ID NO:2, and HCDR3 with an amino acid sequence as shown in SEQ ID NO:3; and / or (2) an amino acid sequence with a sequence similarity of at least 80% with SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3 respectively. The antibody has high affinity, strong blocking ability and stability, and the single-domain antibody has broad application prospects in the treatment of autoimmune diseases.

The invention belongs to the technical field of biological medicine and immunology, and particularly relates to a single-domain antibody targeting cross binding of human and cynomolgus monkey CD46 and application of the single-domain antibody. The alpaca is utilized to generate the nanoscale antibody, the molecular weight of the nanoscale antibody is about 15 kDa, the nanoscale antibody can more efficiently penetrate solid tumor tissues or cross a blood brain barrier, and the binding efficiency of the antibody and a target spot is improved as much as possible. The 11 single-domain antibodies prepared by the invention have the specificity of resisting human and cynomolgus monkey CD46, the binding potency of the 11 single-domain antibodies is remarkably superior to that of an Anti-CD46 humanization antibody in the binding detection of CD46 target protein and CD46 overexpression cells, and the 11 single-domain antibodies can be used for treating tumors. Meanwhile, the single-domain antibody disclosed by the invention has cross-species cross binding capacity, can be directly used for preclinical pharmacodynamics and safety evaluation, does not need to develop a species-specific substitution antibody, and realizes'one target and double effects'.

The invention belongs to the technical field of immunology, and discloses a manganese salt adjuvant system based on dextran particle capsule shrinkage and a preparation method and application thereof.The manganese salt adjuvant system comprises beta-dextran particles GPs of a hollow spherical shell structure from yeast and manganese hydroxide colloid encapsulated in the dextran particles, the preparation method comprises the following steps: soaking the GPs in a MnCl2 solution, after the inner cavity of the GPs fully absorbs the MnCl2 solution, separating the GPs adsorbing MnCl2, then adding the GPs into a NaOH solution, forming stable manganese hydroxide colloid by manganese ions in the inner cavity of the GPs, and washing after separation to obtain the dextran particle encapsulated manganese salt adjuvant system. The GPMnOH particles carry various antigens at the same time in various modes such as electrostatic adsorption, chemical coupling or hydrophobic interaction, and an ideal carrier is provided for co-delivery immunization of the antigens and adjuvants.

The invention relates to the technical field of immunology, in particular to a haemophilus parasuis disease mucosal vaccine as well as a preparation method and application thereof.The haemophilus parasuis disease mucosal vaccine comprises serum type 4 haemophilus parasuis H0040LV4 and serum type 5 haemophilus parasuis H0014LV5 which are preserved in the China Center for Type Culture Collection (CCTCC) on November 10, 2025 and numbered as CCTCC M 20252516 and CCTCC M 20252517; the bivalent haemophilus parasuis bivalent outer membrane vesicle vaccine prepared by secreting outer membrane vesicles has a good immune protection effect on serum type 4 and type 5 haemophilus parasuis, and compared with a control group, pathological changes of tissues such as lungs and livers of a vaccine immune group are obviously relieved. The vaccine has good immunogenicity, can stimulate comprehensive immune response, induce the organism to generate remarkable specific mucosal immunity, and simultaneously induce cellular immunity and humoral immunity response, and has a wide application prospect.

The present invention belongs to the technical fields of molecular biology and immunology, and provides a camelid-derived nanobody that specifically binds to the trypsin analogue TrypLE and its application. It has a heavy chain variable region VHH, and the VHH contains the following CDRs: CDR1 with the amino acid sequence shown in SEQ ID NO:1, CDR2 with the amino acid sequence shown in SEQ ID NO:2, CDR3 with the amino acid sequence shown in SEQ ID NO:3. The VHH includes 4 framework regions of FR1-4, and FR1, FR2, FR3 and FR4 are arranged alternately with CDR1, CDR2 and CDR3 in sequence. It is a nanobody with high neutralizing activity, has a strong binding ability to TrypLE protein, can effectively recognize TrypLE. This nanobody has a small molecular weight, low immunogenicity, better solubility and stability, and a longer CDR region, providing potential application value for the clinical detection of TrypLE residue content.

The application discloses an anti-human TRPS1 monoclonal antibody and a preparation method and application thereof, and belongs to the technical field of immunology. The anti-human TRPS1 monoclonal antibody provided by the application comprises VHCDR1, VHCDR2 and VHCDR3 with the amino acid sequences as shown in SEQ ID NO. 1-3, and VLCDR1, VLCDR2 and VLCDR3 with the amino acid sequences as shown in SEQ ID NO. 4-6. The nucleotide sequences of the heavy chain variable region and the light chain variable region of the monoclonal antibody, an expression cassette containing the nucleotide sequences, an expression vector, a recombinant cell and a recombinant bacterium are also provided. Therefore, the monoclonal antibody can be prepared by using genetic engineering technology, and the risk factors in the production and storage process of the traditional monoclonal antibody can be avoided. The monoclonal antibody prepared by the application has stable properties, high experimental repeatability and high titer, and has good specificity and affinity to the TRPS1 protein.

The application discloses a monoclonal antibody of SARS-CoV-2 N protein and a preparation method and application of a test strip thereof. The red microsphere immunochromatography test strip prepared from the monoclonal antibody of SARS-CoV-2 N protein can quickly and accurately detect SARS-CoV-2 N protein, shortens the detection time, simplifies the detection steps, has the characteristics of being quick and convenient and being suitable for on-site detection, and provides a reliable immunological technology for quickly and efficiently detecting SARS-CoV-2 infection.

The invention provides an anti-Omicro fully-humanized monoclonal antibody 3G5 targeting RBD (Radial Basis Decidosis) and application of the anti-Omicro fully-humanized monoclonal antibody 3G5, and belongs to the technical field of microbiology and immunology. The monoclonal antibody 3G5 comprises a heavy chain variable region and a light chain variable region, and the amino acid sequences of three complementary determining regions of the heavy chain variable region are respectively as follows: GGSISSSSNF, IYYSGST and ARLDLGGDIVVPPAAKPYYYMDV; the amino acid sequences of the three complementary determining regions of the heavy chain variable region are respectively as follows: GGSISSSSNF, IYYSGST and ARLDLGGDIVVPPAAKPYYYMDV; the amino acid sequences of three complementary determining regions of the light chain variable region are respectively SSNIGAGYN, GDI and QSYDSSLSGLYV. The amino acid sequences of the three complementary determining regions are respectively SSNIGAGYN, GDI and QSYDSSLSGLYV. The monoclonal antibody 3G5 provided by the invention has efficient and specific anti-Omicron neutralizing activity, is completely human-derived and good in stability, and has great application potential in preparation of novel coronavirus detection products or drugs for preventing and treating novel coronavirus diseases.

The invention belongs to the technical field of biological medicine and immunology, and particularly relates to a single-domain antibody targeting PD-L1 cross binding of human and cynomolgus monkeys and application of the single-domain antibody. The single-domain antibody disclosed by the invention has the specificity of resisting PD-L1 of human and cynomolgus monkeys, and shows relatively strong binding efficacy in the binding detection of PD-L1 target protein or PD-L1 overexpression cells; in the detection of blocking PD-1 / PD-L1 functions, a part of the single-domain antibodies even show a blocking effect which is obviously superior to that of Atezolizumab, so that the single-domain antibodies prepared by the invention can be used for diagnosis, treatment and prognosis detection of PD-L1 positive tumors. Meanwhile, the single-domain antibody disclosed by the invention has cross-species cross binding capacity, can be directly used for preclinical pharmacodynamics and safety evaluation, does not need to develop a species-specific substitution antibody, and realizes'one target and double effects'.

The invention provides a fully humanized monoclonal antibody for resisting SARS-CoV and SARS-CoV-2 and application of the fully humanized monoclonal antibody, and belongs to the technical field of immunology, and the amino acid sequence of a heavy chain variable region of the monoclonal antibody is as shown in SEQ ID NO: 1; the amino acid sequence of a light chain variable region of the monoclonal antibody SARS2-1 is as shown in SEQ ID NO: 2; the antibody has a unique CDR partition, can identify S proteins of the two viruses at the same time, and has cross-neutralization activity on pseudoviruses of the two viruses. The antibody has the characteristics of high expression, full human source and good stability, is suitable for industrial production, and has potential application value for coping with outbreak prevalence caused by coronavirus possibly occurring at present and in the future.

The invention belongs to the technical field of immunology, and particularly discloses application of 2 ', 3'-cGAMP in preparation of a medicine for enhancing chicken pox-herpes zoster virus vaccine immune response. The 2 ', 3'-cGAMP combined varicella-zoster virus vaccine disclosed by the invention can improve the level of a specific IgG antibody, enhance the cellular immune response intensity of a gE antigen and improve the secretion amount of IFN-gamma and IL-2, so that the immune response of the varicella-zoster virus vaccine is enhanced, the immunoprophylaxis effect is enhanced, and the 2 ', 3'-cGAMP combined varicella-zoster virus vaccine adjuvant can be used for preparing a vaccine adjuvant for treating the varicella-zoster virus. Good application prospects are realized.

The present application relates to the technical field of immunology, and particularly relates to a murine IgG monoclonal antibody, a preparation method and application thereof. The heavy chain variable region of the monoclonal antibody has an amino acid sequence as shown in SEQ ID NO:1; and the light chain variable region has an amino acid sequence as shown in SEQ ID NO:2. The present application further discloses a DNA molecule encoding the antibody, expression of the antibody, and a eukaryotic host cell transformed by the expression vector. The murine IgG monoclonal antibody provided by the present application is preliminarily verified in a 5L bioreactor, and the expression amount is 5.33g / L. It is identified that the monoclonal antibody is used as a blocking agent for evaluation, and the blocking effect is obvious, and plays an important role in the use of blocking agents.